<info type="ChemicalEntity">Serum Amyloid A</info> Induces <info type="DiseaseOrPhenotypicFeature">Inflammation</info>, <info type="DiseaseOrPhenotypicFeature">Proliferation</info> and <info type="DiseaseOrPhenotypicFeature">Cell Death</info> in <info type="CellLine">Activated Hepatic Stellate Cells</info>.

<info type="ChemicalEntity">Serum amyloid A</info> (<info type="GeneOrGeneProduct">SAA</info>) is an evolutionary highly conserved acute phase protein that is predominantly secreted by <info type="GeneOrGeneProduct">hepatocytes</info>. However, its role in <info type="DiseaseOrPhenotypicFeature">liver injury</info> and <info type="DiseaseOrPhenotypicFeature">fibrogenesis</info> has not been elucidated so far. In this study, we determined the effects of <info type="ChemicalEntity">SAA</info> on <info type="CellLine">hepatic stellate cells</info> (<info type="GeneOrGeneProduct">HSCs</info>), the main fibrogenic cell type of the liver. <info type="ChemicalEntity">Serum amyloid A</info> potently activated <info type="GeneOrGeneProduct">IkappaB kinase</info>, <info type="GeneOrGeneProduct">c-Jun N-terminal kinase</info> (<info type="GeneOrGeneProduct">JNK</info>), <info type="GeneOrGeneProduct">Erk</info> and <info type="GeneOrGeneProduct">Akt</info> and enhanced <info type="GeneOrGeneProduct">NF-kappaB</info>-dependent <info type="GeneOrGeneProduct">luciferase</info> activity in primary <info type="CellLine">human</info> and <info type="CellLine">rat HSCs</info>. <info type="ChemicalEntity">Serum amyloid A</info> induced the transcription of <info type="GeneOrGeneProduct">MCP-1</info>, <info type="GeneOrGeneProduct">RANTES</info> and <info type="GeneOrGeneProduct">MMP9</info> in an <info type="GeneOrGeneProduct">NF-kappaB</info>- and <info type="GeneOrGeneProduct">JNK</info>-dependent manner. Blockade of <info type="GeneOrGeneProduct">NF-kappaB</info> revealed cytotoxic effects of <info type="ChemicalEntity">SAA</info> in primary <info type="CellLine">HSCs</info> with signs of <info type="DiseaseOrPhenotypicFeature">apoptosis</info> such as <info type="GeneOrGeneProduct">caspase 3</info> and <info type="GeneOrGeneProduct">PARP</info> cleavage and <info type="GeneOrGeneProduct">Annexin V</info> staining. <info type="ChemicalEntity">Serum amyloid A</info> induced <info type="CellLine">HSC</info> <info type="DiseaseOrPhenotypicFeature">proliferation</info>, which depended on <info type="GeneOrGeneProduct">JNK</info>, <info type="GeneOrGeneProduct">Erk</info> and <info type="GeneOrGeneProduct">Akt</info> activity. In primary <info type="CellLine">hepatocytes</info>, <info type="ChemicalEntity">SAA</info> also activated <info type="GeneOrGeneProduct">MAP kinases</info>, but did not induce relevant <info type="DiseaseOrPhenotypicFeature">cell death</info> after <info type="GeneOrGeneProduct">NF-kappaB</info> inhibition. In two models of <info type="DiseaseOrPhenotypicFeature">hepatic fibrogenesis</info>, <info type="ChemicalEntity">CCl4</info> treatment and <info type="ChemicalEntity">bile duct ligation</info>, hepatic <info type="GeneOrGeneProduct">mRNA</info> levels of <info type="GeneOrGeneProduct">SAA1</info> and <info type="GeneOrGeneProduct">SAA3</info> were strongly increased. In conclusion, <info type="ChemicalEntity">SAA</info> may modulate fibrogenic responses in the liver in a positive and negative fashion by inducing <info type="DiseaseOrPhenotypicFeature">inflammation</info>, <info type="DiseaseOrPhenotypicFeature">proliferation</info> and <info type="DiseaseOrPhenotypicFeature">cell death</info> in <info type="CellLine">HSCs</info>.